Long-Acting Injection Better for PrEP in Men, Gender-Diverse Groups

(MedPage Today) -- Twice-yearly lenacapavir (Sunlenca) substantially reduced HIV infection when used for preexposure prophylaxis (PrEP) in cisgender men and transgender or gender-nonbinary persons in the pivotal PURPOSE 2 trial.
Injections every...